By Olga Cotaga

LONDON--AstraZeneca PLC (AZN.LN) said on Tuesday that its prescription blood thinner, Brilinta, was no more beneficial than clopidogrel following its EUCLID clinical trial on patients with symptomatic peripheral artery disease.

The U.K.-based drugmaker's executive vice president, Sean Bohen, said: "The proven benefits of Brilinta in acute coronary syndrome and post-myocardial infarction patients are established and remain unchanged."

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

October 04, 2016 02:43 ET (06:43 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Astrazeneca Charts.